Langar Global HealthTech ETF

ResMed and Oura Partner to Enhance Sleep Health Education and Care Pathways for US Members

Resona Asset Management Reduces Stake in Intuitive Surgical by 13.1%

FAMAR Group Signs Contract Manufacturing Agreement with GE HealthCare to Expand Iodine Contrast Agent Capacity

Moderna President Stephen Hoge Sells 53,336 Shares at $48.4 and Exercises Options

Bank of America Lowers Intuitive Surgical Target Price to $520, Maintains Buy Rating

Dexcom Announces Launch of Dexcom Flex Continuous Glucose Monitoring System in Germany

Philips Consortium Signs 8-Year Contract with Stockholm for Remote Home Hospital Care

Zimmer Biomet Raises 2026 Buyback and Earnings Forecasts, Stock Rises Short-Term

GEHC Receives 'Hold' Consensus from 17 Brokers, Executives Buy Shares to Show Confidence

Barclay's Analyst Matt Miksic Maintains Sell Rating on Dexcom with $64 Target

Dexcom Investor Day: Focus on G8 New Product, Doubling US CGM Coverage, and International Expansion Strategy

Wall Street Zen Upgrades Intuitive Surgical to Buy; Earnings and Revenue Beat Expectations

Moderna Stock Surges 13% Amid Hantavirus Outbreak; Analysts Cite Limited Commercialization Potential

Dexcom Announces 2030 Targets: 10% Revenue Growth and $10B Buyback

RBC Capital Analyst Maintains Hold Rating on Royal Philips with a Price Target of €25

Macquarie and Citibank Reiterate Buy Rating on ResMed CHESS Depositary Interests

Arbutus Biopharma reports Q1 2026 net income of $169.7 million

Moderna Recognized for mRNA Achievements and Approved for Flu and COVID Combo Vaccine

IQVIA Reports Strong Q1 Earnings and Raises Full-Year Guidance

GE HealthCare to Showcase AI-driven Radiotherapy Tools at ESTRO 2026

Meiwu Tech

Amesite

InMed Pharmaceuticals

Generation Income Properties

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Co-Diagnostics

MetaVia

BAYVIEW ACQUISITION CORPORATION COM USD0.0001 (S/R) 17/11/2028

Phoenix Asia

Gen Digital - Rights

DOCS

HEAL

LGHT

Barclays has downgraded Doximity (NYSE:DOCS) from a 'strong-buy' to a 'hold' rating. Other analysts have also reduced their price targets, with Mizuho lowering it to $26, Goldman Sachs to $24, and BMO to $20. Doximity's stock currently has a consensus rating of 'Hold' and a target price of $30.62. The company has a market cap of $3.50 billion and recently approved a $500 million stock buyback program.

Market Beat

Doximity

Global X HealthTech ETF

First Trust Nasdaq Lux Digital Health Solutions ETF

Barclays

Mizuho Financial

Mizuho Financial Group, Inc.

Goldman Sachs

Bank of Montreal

Atlantic Union Bankshares

GS Hldg R

ATLANTIC UNION BANKSHARES CORP 6.875% DEP SH RP 1/400 NON CU PR PF SR A

Atlantic Union Bankshares Corporation

Barclays Downgrades Doximity (NYSE:DOCS) to Hold

Doximity, Inc. (NYSE:DOCS) has received a consensus recommendation of 'Moderate Buy' from 24 analysts. Thirteen rated it as hold, nine as buy, and two as strong buy. The average 12-month target price is $30.62. Recent analyst reports show varied price targets, with BMO Capital Markets lowering theirs to $20 and Piper Sandler raising it to $42. Insider transactions revealed significant stock sales, and institutional investors hold 87.19% of shares.

Piper Sandler Cos

Morgan Stanley

Evercore

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Doximity, Inc. (NYSE:DOCS) Given Average Recommendation of "Moderate Buy" by Analysts

JPMorgan Chase & Co. has lowered its price target for Doximity (NYSE:DOCS) from $33.00 to $28.00, maintaining a "neutral" rating. This suggests a potential upside of 60.38% from the previous close. Other brokerages have also adjusted their targets, with Robert W. Baird setting a target of $18.00, BMO Capital Markets at $20.00, and Bank of America at $47.00. Doximity's stock traded down to $17.46, with a market cap of $3.22 billion. Insiders have sold shares recently, indicating potential concerns about the stock's valuation.

JPMorgan Chase

Defiance Daily Target 2X Long JPM ETF

JPMorgan Chase & Co. Lowers Doximity (NYSE:DOCS) Price Target to $28.00

AVAH

BIIB

Healthcare stocks declined on Thursday, with the NYSE Healthcare Index down 0.1%. Biogen shares fell nearly 6% after a failed Alzheimer's trial. Prestige Consumer Healthcare reported disappointing Q4 results and lowered 2026 guidance, leading to an 8% drop in shares. Doximity's shares dropped over 24% after issuing weak guidance, despite long-term growth potential. In contrast, Aveanna Healthcare shares rose 11% following strong Q1 earnings and an increased revenue forecast for 2026.

Fidelity

Aveanna Healthcare

Biogen

Prestige Brands

SPDR S&P Biotech

iShares US Healthcare Providers

iShares US Healthcare

SPDR S&P Health Equip

VG Health

iShares US Pharma

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

iShares Global Healthcare

Direxion S&P Biotech Bull 3X

iShares Genomics Immunology and Healthcare ETF

iShares US Medical Devices

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

SPDR S&P Health

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

Sector Update: Healthcare Stocks Softer Thursday Afternoon

Doximity (DOCS) shares dropped 24% following mixed Q4 results and a weaker FY2027 outlook, prompting analysts to downgrade ratings. Wells Fargo's Stan Berenshteyn lowered the rating to Hold and cut the price target to $18, citing risks in AI competition and rising costs. BTIG's David Larsen also downgraded the stock, highlighting a challenging macro environment and weak pharma demand. Despite the downturn, analysts maintain a Moderate Buy consensus on DOCS, with an average price target of $28.12, suggesting a potential upside of 56.91%.

Tip Ranks

Wells Fargo

Veeva Systems -CL

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Why Is Doximity Stock (DOCS) Falling Today, 5/14/26?

Doximity shares fell 24% following disappointing Q4 results, prompting analysts to downgrade ratings and lower price targets. KeyBanc Capital Markets downgraded the stock from Overweight to Sector Weight, citing weak fiscal 2027 growth guidance of 3%-5% and challenges in the pharma ad market. Needham maintained a Buy rating but reduced the price target from $55 to $27, noting revenue growth of 5.1% year-on-year but concerns over decelerating growth. Doximity's stock was trading at $17.70 at the time of the report.

Doximity Sinks 24% As AI Push Fails To Ease Growth Fears

Doximity (DOCS) fell approximately 25% to an all-time low following disappointing Q4 fiscal 2026 results, leading to a downgrade by KeyBanc Capital Markets. The company's guidance did not meet Wall Street expectations, marking the lowest stock price since its IPO in 2021.

KeyCorp

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

Doximity hits an all-time low after Q4 results; KeyBanc downgrades

Doximity (NYSE:DOCS) reached a new 52-week low of $17.32 following insider selling, with shares last trading at $17.8060. Insider Siddharth Sitaram sold 2,309 shares at $25.77, while Director Kira Scherer Wampler sold 9,000 shares at $26.06. Analysts have mixed views, with price targets ranging from $18.00 to $34.00. Despite reporting a 5.1% revenue increase, the company missed earnings expectations and provided lower revenue guidance for FY2027, raising concerns about growth. Doximity's board approved a $500 million stock repurchase program, indicating confidence in the stock's value.

Doximity (NYSE:DOCS) Sets New 52-Week Low After Insider Selling

Doximity, Inc.'s average stock price target has been reduced from $36.74 to $31.11, indicating a potential upside of approximately 33% based on the May 13 closing price. The forecasts from 22 analysts range from $17 to $55 per share. The consensus rating remains a 'Buy' from 25 analysts, with 13 Buys, 12 Holds, and no Sells. This information is sourced from FactSet and does not constitute investment advice.

TradingView

Factset Research

Doximity, Inc. Stock 12‑Month Price Target Cut to $28.11, Implies 20% Upside

Needham & Company LLC has lowered its price target for Doximity (NYSE:DOCS) from $55.00 to $27.00 while maintaining a "buy" rating. This suggests a potential upside of 14.82% from the current price. Other analysts have also adjusted their ratings, with BTIG Research downgrading to "neutral" and JPMorgan reducing their target to $33.00. Doximity's stock opened at $23.52, with a market cap of $4.34 billion. The company has initiated a $500 million share repurchase plan, indicating management's belief in the stock's undervaluation.

ROYAL BANK OF CANADA

UBS Group AG

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Doximity (NYSE:DOCS) Given New $27.00 Price Target at Needham & Company LLC

Langar Global HealthTech ETF(LGHT.US)